Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 45, 2013 - Issue 7
Submit an article Journal homepage
363
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial

Lars-Magnus AnderssonFrom the Department of Infectious Diseases, Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenCorrespondence[email protected]
,
Jan VesterbackaFrom the Department of Medicine, Division of Infectious Diseases, Karolinska Institute, Stockholm, Sweden
,
Anders BlaxhultFrom the Department of Medicine, Division of Infectious Diseases, Karolinska Institute, Stockholm, Sweden
,
Leo FlamholcFrom the Department of Infectious Diseases, Malmo University Hospital, Malmo, Sweden
,
Staffan NilssonFrom the Department of Mathematical Statistics, Chalmers University of Technology, Gothenburg, Sweden
,
Vidar OrmaasenFrom the Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway
,
Anders SönnerborgFrom the Department of Medicine, Division of Infectious Diseases, Karolinska Institute, Stockholm, Sweden
&
Magnus GisslénFrom the Department of Infectious Diseases, Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
 show all
Pages 543-551 | Received 26 Nov 2012, Accepted 04 Dec 2012, Published online: 07 Jan 2013

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Qing Wang, Jim Young, Enos Bernasconi, Pietro Vernazza, Alexandra Calmy, Matthias Cavassini, Hansjakob Furrer, Jan Fehr, Heiner C. Bucher & Manuel Battegay. (2014) Virologic and Immunologic Responses in Treatment-Naive Patients to Ritonavir-Boosted Atazanavir or Efavirenz With a Common Backbone. HIV Clinical Trials 15:3, pages 92-103.
Read now

Articles from other publishers (12)

Enrico Ripamonti, Arvid Edén, Staffan Nilsson, Anders Sönnerborg, Henrik Zetterberg & Magnus Gisslén. (2022) Longitudinal decline of plasma neurofilament light levels after antiretroviral initiation in people living with HIV. Journal of Internal Medicine 293:4, pages 445-456.
Crossref
Sonya J. Snedecor, Matthew Radford, David Kratochvil, Richard Grove & Yogesh S. Punekar. (2019) Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infectious Diseases 19:1.
Crossref
Shashi N Kapadia, Robert R Grant, Susan B German, Baljinder Singh, Amy L Davidow, Shobha Swaminathan & Sally Hodder. (2018) HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens. SAGE Open Medicine 6, pages 205031211881691.
Crossref
Amr Menshawy, Ammar Ismail, Abdelrahman Ibrahim Abushouk, Hussien Ahmed, Esraa Menshawy, Ahmed Elmaraezy, Mohamed Gadelkarim, Mohamed Abdel-Maboud, Attia Attia & Ahmed Negida. (2017) Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis. Archives of Virology 162:8, pages 2181-2190.
Crossref
Álvaro H. Borges, Andreas Lundh, Britta Tendal, John A. Bartlett, Nathan Clumeck, Dominique Costagliola, Eric S. Daar, Patrícia Echeverría, Magnus Gisslén, Tania B. Huedo-Medina, Michael D. Hughes, Katherine Huppler Hullsiek, Paul Khabo, Stephanus Komati, Princy Kumar, Shahin Lockman, Rodger D. MacArthur, Franco Maggiolo, Alberto Matteelli, Jose M. Miro, Shinichi Oka, Kathy Petoumenos, Rebekah L. Puls, Sharon A. Riddler, Paul E. Sax, Juan Sierra-Madero, Carlo Torti & Jens D. Lundgren. (2016) Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor–based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. Clinical Infectious Diseases 63:2, pages 268-280.
Crossref
Nathan Ford, Zara Shubber, Anton Pozniak, Marco Vitoria, Meg Doherty, Catherine Kirby & Alexandra Calmy. (2015) Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 69:4, pages 422-429.
Crossref
Joanna Kryst, Paweł Kawalec & Andrzej Pilc. (2015) Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLOS ONE 10:5, pages e0124279.
Crossref
. (2015) Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases 60:8, pages 1262-1268.
Crossref
Massimiliano Fabbiani, Mauro Zaccarelli, Pierfrancesco Grima, Mattia Prosperi, Iuri Fanti, Manuela Colafigli, Alessandro D’Avino, Annalisa Mondi, Alberto Borghetti, Massimo Fantoni, Roberto Cauda & Simona Di Giambenedetto. (2014) Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients. BMC Infectious Diseases 14:1.
Crossref
Dipen A. Patel, Sonya J. Snedecor, Wing Yu Tang, Lavanya Sudharshan, Jessica W. Lim, Robert Cuffe, Sonia Pulgar, Kim A. Gilchrist, Rodrigo Refoios Camejo, Jennifer Stephens & Garrett Nichols. (2014) 48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis. PLoS ONE 9:9, pages e105653.
Crossref
Jean B. Nachega, Jean-Jacques Parienti, Olalekan A. Uthman, Robert Gross, David W. Dowdy, Paul E. Sax, Joel E. Gallant, Michael J. Mugavero, Edward J. Mills & Thomas P. Giordano. (2014) Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clinical Infectious Diseases 58:9, pages 1297-1307.
Crossref
Valérie Potard, David Rey, Isabelle Poizot-Martin, Saadia Mokhtari, Christian Pradier, Willy Rozenbaum, Françoise Brun-Vezinet & Dominique Costagliola. (2014) Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis. Journal of the International AIDS Society 17:1, pages 19070.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.